Logo Stallergenes

APPOINTMENT OF CHRISTIAN CHAVY AS CHIEF EXECUTIVE OFFICER OF STALLERGENES

Publié le 11 mars 2014

 

 

Antony (France), 5 March 2014 – During its meeting held on March 5, 2014, the Board of Directors of Stallergenes announced the appointment of Christian CHAVY as Chief Executive Officer, to replace Roberto GRADNIK. This appointment will be effective on March 31, 2014.

 

The appointment of Christian CHAVY will enable the Group to pursue its strategy and to support Stallergenes in promising markets for immunotherapy, with a particular focus on the US market.

 

Roberto GRADNIK will ensure a smooth transition and will provide consultancy services to the Board of Directors during a four-month transitional period.

 

Patrick LANGLOIS, Chairman of the Board of Directors, commented:

 

“On behalf of the Board of Directors, I would like to warmly thank Roberto GRADNIK, who has successfully implemented a new organization adapted to the new operational challenges faced by the Group. Under his leadership, the Group made a major breakthrough, with the preparation and submission of the application for commercial authorisation of Oralair®tablets in the US, which is currently reviewed by the FDA, and the definition of a long-term strategy, with a particularly strong focus on international markets. The appointment of Christian CHAVY represents a continuation of this strategy. His recognised management skills, his international experience and considerable knowledge of the pharmaceuticals industry will enable Stallergenes to continue its expansion into promising markets for immunotherapy and in particular to ensure the success of Oralair® in the US market.”

 

In 2010, Christian CHAVY joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals (USA, Europe, Japan and rest of the world). Prior to joining Actelion, he was Vice President at the reproductive medicine strategic unit of Serono in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY is a graduate of ESSEC and Institut de Contrôle de Gestion de Paris (ICG).

 

About STALLERGENES

 

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks to its innovation strategy, fueled by investments amounting to around 20% of total annual revenues as well as external cooperations, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

 

STALLERGENES operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of € 248 million, and more than 500,000 patients were treated with STALLERGENES products.

For more information please visit the company website at: www.stallergenes.com

 

 

Euronext Paris (Compartment B)

CAC small

ISIN: FR0000065674

Reuters: GEN.PA

Bloomberg: GEN.FP

 

 

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes’ management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

Contacts:

 

Investor and analyst relations

Peter Buhler

Chief Financial Officer

Phone: +33 1 55 59 20 95

Email: investorrelations@stallergenes.com

 

Investor and press relations agency

FTI Consulting – Analyst and investor contact

Stephan Dubosq

Phone: +33 1 47 03 68 16

Email:stephan.dubosq@fticonsulting.com

 

 

 

 

 

Media Relations

Lise Lemonnier

Senior Communication & Public Affairs Director

Phone: + 33 1 55 59 20 96

Email: llemonnier@stallergenes.com

 

 

FTI Consulting – Press contact                                 

Jeanne Bariller    

Phone: +33 1 47 03 68 63 

                                                                                              

Email:jeanne.bariller@fticonsulting.com                          

 

 

 

Revenir à la liste des articles
contact -plan de site - mentions légales

copyright 2011 G5